ScholarIQanswers from OpenAlex

Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial

PaperCitations, authors & open-access status

Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial have?

ScholarIQcitation count

Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial has 49 citations in the OpenAlex counts ScholarIQ stores.

When was Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial published?

ScholarIQyear

Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial has 2024 year in the ScholarIQ index.

What is the open-access status of Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial?

ScholarIQoa status

Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial has hybrid oa status in the ScholarIQ index.

What is the DOI of Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial?

ScholarIQdoi

The DOI for Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial is on the source record.

What is the PMID of Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial?

ScholarIQpmid

The PMID for Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial is on the source record.

What is the OpenAlex record for Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial?

ScholarIQopenalex

The OpenAlex for Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial